Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observationShaun G. Goodman, Ivan Pećin, Michael Szarek et al.|European Heart Journal - Cardiovascular Pharmacotherapy|2024Cited by 24